NASDAQ:AMRN Amarin (AMRN) Stock Price, News & Analysis $10.57 -0.69 (-6.13%) Closing price 04:00 PM EasternExtended Trading$10.56 -0.01 (-0.09%) As of 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Amarin Stock (NASDAQ:AMRN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Amarin alerts:Sign Up Key Stats Today's Range$10.56▼$11.3050-Day Range$11.26▼$14.0052-Week Range$10.56▼$17.31Volume177,890 shsAverage Volume76,552 shsMarket Capitalization$222.71 millionP/E RatioN/ADividend YieldN/APrice Target$13.00Consensus RatingSell Company Overview Amarin Corporation plc is a biopharmaceutical company focused on cardiovascular health. Its principal product is VASCEPA, a prescription medicine containing icosapent ethyl, an omega-3 fatty acid derivative. In the United States, VASCEPA is approved for use with a statin and other measures to reduce the risk of certain cardiovascular events in eligible adults with elevated triglycerides. It is also approved as an adjunct to diet to lower triglyceride levels in adults with severe hypertriglyceridemia. Amarin has also pursued markets outside the United States through partnerships. In Europe, icosapent ethyl is marketed under the name Vazkepa for eligible patients at high cardiovascular risk. The company’s business centers on developing and commercializing this treatment and supporting its use in cardiovascular care.AI Generated. May Contain Errors. Read More Amarin Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreAMRN MarketRank™: 1.74458459007 of 5 starsAmarin scored higher than 35% of companies evaluated by MarketBeat, and ranked 732nd out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.8 / 5Analyst RatingSell Consensus RatingAmarin has received a consensus rating of Sell. The company's average rating score is 1.33, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 2 sell ratings.Upside PotentialAmarin has a consensus price target of $13.00, representing about 22.2% upside from its current price of $10.64.Amount of Analyst CoverageAmarin has only been the subject of 2 research reports in the past 90 days.Read more about Amarin's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Amarin are expected to grow in the coming year, from ($0.85) to ($0.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amarin is -11.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amarin is -11.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmarin has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.66% of the float of Amarin has been sold short.Short Interest Ratio / Days to CoverAmarin has a short interest ratio ("days to cover") of 7.58.Change versus previous monthShort interest in Amarin has recently increased by 0.98%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAmarin does not currently pay a dividend.Dividend GrowthAmarin does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment-0.03 News SentimentAmarin has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Amarin this week, compared to 4 articles on an average week.Search Interest2 people have searched for AMRN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Amarin insiders have not sold or bought any company stock.Percentage Held by Insiders4.21% of the stock of Amarin is held by insiders.Percentage Held by Institutions22.25% of the stock of Amarin is held by institutions.Read more about Amarin's insider trading history. Receive AMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AMRN Stock News HeadlinesAmarin Reports Immediate Resignation of Company DirectorNovember 18 at 5:51 PM | tipranks.comAmarin Earnings Call Highlights Profitability and Global GrowthNovember 17 at 8:22 AM | theglobeandmail.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 20 at 1:00 AM | Weiss Ratings (Ad)Amarin (NASDAQ:AMRN) Stock Moved Up to Buy by Wall Street ZenNovember 16, 2026 | americanbankingnews.comAmarin: 3 Key Takeaways for Long-Term InvestorsNovember 11, 2026 | fool.comAmarin Presents New Cardiovascular Risk Data on Lipoprotein(a) and EPA at AHA Scientific Sessions 2026November 9, 2026 | yahoo.comAmarin Highlights New Data on Lipoprotein(a) and other Apolipoprotein B Containing Lipoproteins at American Heart Association (AHA) Scientific Sessions 2026November 9, 2026 | finance.yahoo.comAmarin Highlights New Data on Lipoprotein(a) and other Apolipoprotein B Containing Lipoproteins at American Heart Association (AHA) Scientific Sessions 2026November 9, 2026 | globenewswire.comSee More Headlines AMRN Stock Analysis - Frequently Asked Questions How have AMRN shares performed this year? Amarin's stock was trading at $13.95 at the start of the year. Since then, AMRN stock has decreased by 23.8% and is now trading at $10.6350. How were Amarin's earnings last quarter? Amarin Corporation PLC (NASDAQ:AMRN) announced its quarterly earnings results on Wednesday, February, 25th. The biopharmaceutical company reported $0.01 EPS for the quarter, beating the consensus estimate of ($1.27) by $1.28. The biopharmaceutical company had revenue of $49.22 million for the quarter, compared to analyst estimates of $50.62 million. Amarin had a negative net margin of 10.87% and a negative trailing twelve-month return on equity of 0.52%. Read the conference call transcript. When did Amarin's stock split? Amarin's stock reverse split before market open on Friday, April 11th 2025.The 1-20 reverse split was announced on Wednesday, March 12th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 10th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Does Amarin have any subsidiaries? Amarin subsidiaries include these companies: Ester Neurosciences, Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharmaceuticals Ireland Limited, Amarin Pharma Inc., Amarin Switzerland GmbH, Amarin UK Limited, and Ester Neurosciences Limited. Who are Amarin's major shareholders? Top institutional shareholders of Amarin include Brooklands Fund Management Ltd (1.03%), LCM Capital Management Inc (0.28%), R Squared Ltd (0.23%) and State Street Corp (0.13%). Insiders that own company stock include Aaron Berg, Steven B Ketchum and Patrick Holt. View institutional ownership trends. How do I buy shares of Amarin? Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amarin own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amarin investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Tesla (TSLA), Block (XYZ) and Canopy Growth (CGC). Company Calendar Today11/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 7 days, AMRN's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:AMRN CIK897448 Webwww.amarincorp.com Phone(531) 669-9020FaxN/AEmployees80Year Founded1991Price Target and Rating Average Price Target for Amarin$13.00 High Price Target$13.00 Low Price Target$13.00 Potential Upside/Downside+23.0%Consensus RatingSell Rating Score (0-4)1.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$38.80 million Net Margins-10.87% Pretax Margin-9.73% Return on Equity-0.52% Return on Assets-0.36% Debt Debt-to-Equity RatioN/A Current Ratio3.50 Quick Ratio2.59 Sales & Book Value Annual Sales$213.65 million Price / Sales1.04 Cash Flow$0.34 per share Price / Cash Flow31.19 Book Value$21.09 per share Price / Book0.50Miscellaneous Outstanding Shares21,070,000Free Float20,186,000Market Cap$222.71 million OptionableOptionable Beta0.81 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:AMRN) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredA little-known law has been quietly applied to your savings for years.Fox News reported that under current law, legal title to most stocks and bonds sits with a central institution...Monetary Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Corporation PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Amarin With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.